Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Checkpoint Inhibitors | Systematic Review

Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review

Authors: Yusheng Guo, Yao Pan, Jiayu Wan, Bingxin Gong, Yi Li, Xuefeng Kan, Chuansheng Zheng

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Although numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), the prognostic value of the LIPI in a pancancer setting remains unclear.

Methods

A comprehensive search was conducted until July 2023 across the PubMed, Embase, Web of Science, and Cochrane Library databases to identify relevant studies evaluating the prognostic value of the LIPI in cancer patients treated with ICIs. The outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). We described and compared the pooled outcomes by stratifying the patients based on different groupings of LIPI (good vs. intermediate [0 vs. 1], good vs. poor [0 vs. 2], and good vs. intermediate / poor [0 vs. 1 + 2]).

Results

A total of 9959 patients in 35 studies were included. A higher score of LIPI was associated with impaired OS. The pooled HRs were 1.69 (95% CI: 1.55–1.85, p < 0.001; 0 vs. 1), 3.03 (95% CI: 2.53–3.63, p < 0.001; 0 vs. 2), and 2.38 (95% CI: 1.97–2.88, p < 0.001; 0 vs. 1 + 2). A higher LIPI score was associated with shorter PFS. The pooled HRs were 1.41 (95% CI: 1.31–1.52, p < 0.001; 0 vs. 1), 2.23 (95% CI: 1.87–2.66, p < 0.001; 0 vs. 2), and 1.65 (95% CI: 1.46–1.86, p < 0.001; 0 vs. 1 + 2). Similarly, a higher LIPI score was associated with a lower ORR. The pooled ORs were 0.63 (95% CI: 0.54–0.75, p < 0.001; 0 vs. 1) and 0.38 (95% CI: 0.29–0.50, p < 0.001; 0 vs. 2). A higher LIPI score was associated with a lower DCR. The pooled ORs were 0.47 (95% CI: 0.35–0.61, p < 0.001; 0 vs. 1) and 0.19 (95% CI: 0.12–0.30, p < 0.001; 0 vs. 2).

Conclusion

In patients with NSCLC or other solid tumours, the lung immune prognostic index could robustly stratify the clinical outcomes into three groups among the patients who receive ICIs. LIPI is a low-cost, simple, accessible, and accurate prognostic tool in a pancancer setting and it may contribute to the evaluation of risk stratification in patients treated with ICIs.
Appendix
Available only for authorised users
Literature
1.
Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.PubMedPubMedCentralCrossRef
2.
3.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T-Cell exhaustion signatures vary with tumor type and are severe in Glioblastoma. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(17):4175–86.CrossRef
4.
Gu SS, Wang X, Hu X, Jiang P, Li Z, Traugh N, et al. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020;21(1):263.PubMedPubMedCentralCrossRef
5.
Guo Y, Xiang D, Wan J, Yang L, Zheng C. Focus on the dynamics of Neutrophil-to-lymphocyte ratio in Cancer patients treated with Immune Checkpoint inhibitors: a Meta-analysis and systematic review. Cancers (Basel). 2022;14(21).
6.
Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO open. 2019;4(1):e000442.PubMedPubMedCentralCrossRef
7.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207–18.PubMedCrossRef
8.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–39.PubMedCrossRef
9.
Guven DC, Sahin TK, Erul E, Cakir IY, Ucgul E, Yildirim HC et al. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. J Clin Med. 2022;11(15).
10.
Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med. 2020;12(526).
11.
Sionov RV, Fridlender ZG, Granot Z. The multifaceted roles neutrophils play in the Tumor Microenvironment. Cancer Microenvironment: Official J Int Cancer Microenvironment Soc. 2015;8(3):125–58.CrossRef
12.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.PubMedCrossRef
13.
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.PubMedCrossRef
14.
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(22):5487–96.CrossRef
15.
Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, et al. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer. 2017;117(11):1607–13.PubMedPubMedCentralCrossRef
16.
Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (Stockholm Sweden). 2015;54(7):961–70.CrossRef
17.
Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic value of the lung Immune Prognostic Index for patients treated for metastatic non-small cell Lung Cancer. JAMA Oncol. 2019;5(10):1481–5.PubMedPubMedCentralCrossRef
18.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung Immune Prognostic Index with Immune checkpoint inhibitor outcomes in patients with Advanced Non-small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351–7.PubMedPubMedCentralCrossRef
19.
Xie J, Chen M, Han H, Xu K, Qiu G, Lin X, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: a real-world multicenter propensity score-matched study. Thorac cancer. 2023;14(15):1327–38.PubMedPubMedCentralCrossRef
20.
Sun T, Guo Y, Sun B, Chen L, Ren Y, Zhu L, et al. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma. Eur J Med Res. 2023;28(1):225.PubMedPubMedCentralCrossRef
21.
Parent P, Auclin E, Patrikidou A, Mezquita L, Martínez Chanzá N, Dumont C et al. Prognostic value of the lung Immune Prognosis Index score for patients treated with Immune Checkpoint inhibitors for Advanced or metastatic urinary tract carcinoma. Cancers (Basel). 2023;15(4).
22.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, et al. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. Cancer Immunol Immunotherapy: CII. 2023;72(6):1709–23.PubMedCrossRef
23.
Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P et al. Predicting Immunotherapy outcomes in older patients with solid tumors using the LIPI score. Cancers (Basel). 2022;14(20).
24.
Pan Y, Si H, Jia R, Deng G, Yan H, Fan M, et al. Analysis of a systemic inflammatory biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 therapy: prognostic and predictive significance of Lung Immune Prognostic Index score. J Oncol. 2022;2022:1427779.PubMedPubMedCentralCrossRef
25.
Gou M, Qian N, Zhang Y, Wei L, Fan Q, Wang Z, et al. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol. 2022;13:950868.PubMedPubMedCentralCrossRef
26.
Chen S, Guo S, Gou M, Pan Y, Fan M, Zhang N, et al. A composite indicator of derived neutrophil-lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors. Front Oncol. 2022;12:951985.PubMedPubMedCentralCrossRef
27.
Assié JB, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A et al. Immune-Checkpoint inhibitors for malignant pleural mesothelioma: a French, Multicenter, Retrospective Real-World Study. Cancers (Basel). 2022;14(6).
28.
Li L, Pi C, Yan X, Lu J, Yang X, Wang C, et al. Prognostic value of the pretreatment lung Immune Prognostic Index in Advanced Small Cell Lung Cancer patients treated with First-Line PD-1/PD-L1 inhibitors plus chemotherapy. Front Oncol. 2021;11:697865.PubMedPubMedCentralCrossRef
29.
Hou B, Wang P, Liu T, Chen S, Li T, Zhang S, et al. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. Clin Res Hepatol Gastroenterol. 2021;45(5):101748.PubMedCrossRef
30.
Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, et al. Association of the lung Immune Prognostic Index with Immunotherapy outcomes in Mismatch Repair deficient tumors. Cancers (Basel). 2021;13:15.CrossRef
31.
Chen S, Huang Z, Jia W, Tao H, Zhang S, Ma J, et al. Association of the pretreatment lung Immune Prognostic Index with Survival outcomes in Advanced Hepatocellular Carcinoma patients treated with PD-1 inhibitors. J Hepatocellular Carcinoma. 2020;7:289–99.CrossRef
32.
Al Darazi G, Martin E, Delord JP, Korakis I, Betrian S, Estrabaut M et al. Improving patient selection for immuno-oncology phase 1 trials: external validation of six prognostic scores in a French Cancer Center. Int J Cancer. 2020.
33.
Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M et al. The Lung Immune Prognostic Index discriminates survival outcomes in patients with Solid Tumors Treated with Immune Checkpoint inhibitors. Cancers (Basel). 2019;11(11).
34.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef
35.
Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, Cortegoso A, Afonso-Afonso FJ, de Dios-Álvarez N, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Translational lung cancer Res. 2019;8(6):1078–85.CrossRef
36.
Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the lung Immune Prognostic Index for Prediction of Survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(8):1440–6.CrossRef
37.
Mazzaschi G, Minari R, Zecca A, Cavazzoni A, Ferri V, Mori C, et al. Soluble PD-L1 and circulating CD8 + PD-1 + and NK cells enclose a Prognostic and Predictive Immune Effector score in Immunotherapy treated NSCLC patients. Lung cancer (Amsterdam. Netherlands). 2020;148:1–11.
38.
Wang W, Huang Z, Yu Z, Zhuang W, Zheng W, Cai Z, et al. Prognostic value of the lung Immune Prognostic Index May Differ in patients treated with Immune checkpoint inhibitor monotherapy or combined with chemotherapy for non-small cell Lung Cancer. Front Oncol. 2020;10:572853.PubMedPubMedCentralCrossRef
39.
Ali WAS, Hui P, Ma Y, Wu Y, Zhang Y, Chen Y, et al. Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. Ann Transl Med. 2021;9(22):1639.PubMedPubMedCentralCrossRef
40.
Grosjean HAI, Dolter S, Meyers DE, Ding PQ, Stukalin I, Goutam S et al. Effectiveness and safety of First-Line Pembrolizumab in older adults with PD-L1 positive non-small cell Lung Cancer: a retrospective cohort study of the Alberta Immunotherapy Database. Current oncology (Toronto, Ont). 2021;28(5):4213–22.
41.
Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ. Value of the lung Immune Prognostic Index in patients with Non-small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 trial. Cancers (Basel). 2021;13(5).
42.
Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO open. 2021;6(5):100254.PubMedPubMedCentralCrossRef
43.
Sheng J, Li H, Yu X, Yu S, Chen K, Pan G, et al. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: a real-world retrospective study in China. Thorac cancer. 2021;12(22):3019–31.PubMedPubMedCentralCrossRef
44.
Veccia A, Sforza V, Vattemi E, Inno A, Kinspergher S, Dipasquale M, et al. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. Immunotherapy. 2021;13(13):1093–103.PubMedCrossRef
45.
Chen J, Wei S, Zhao T, Zhang X, Wang Y, Zhang X. Clinical significance of serum biomarkers in Stage IV Non-small-cell Lung Cancer treated with PD-1 inhibitors: LIPI score, NLR, dNLR, LMR, and PAB. Dis Markers. 2022;2022:7137357.PubMedPubMedCentralCrossRef
46.
De Giglio A, Tassinari E, Zappi A, Di Federico A, Lenzi B, Sperandi F et al. The Palliative Prognostic (PaP) score without clinical evaluation predicts early mortality among Advanced NSCLC patients treated with immunotherapy. Cancers (Basel). 2022;14(23).
47.
Ortega-Franco A, Hodgson C, Raja H, Carter M, Lindsay C, Hughes S, et al. Real-World Data on Pembrolizumab for pretreated non-small-cell Lung Cancer: clinical outcome and relevance of the lung Immune Prognostic Index. Target Oncol. 2022;17(4):453–65.PubMedCrossRef
48.
Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, et al. Predictive factors correlated with the development of Immune-related adverse events in patients with Non-small Cell Lung Cancer treated with Immune Checkpoint inhibitors. Cancer Manage Res. 2022;14:427–35.CrossRef
49.
Uehara Y, Hakozaki T, Kitadai R, Narita K, Watanabe K, Hashimoto K, et al. Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy. Translational lung cancer Res. 2022;11(2):135–49.CrossRef
50.
Diker O, Olgun P, Balyemez U, Sigit Ikiz S. Development of a Novel Predictive-Prognostic Scoring Index for Immune checkpoint inhibitors in Advanced Non-small Cell Lung Cancer. Cureus. 2023;15(1):e33234.PubMedPubMedCentral
51.
Inoue Y, Inui N, Karayama M, Asada K, Matsuura S, Ikeda M, et al. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149(7):2963–74.PubMedCrossRef
52.
Knetki-Wróblewska M, Tabor S, Piórek A, Płużański A, Winiarczyk K, Zaborowska-Szmit M et al. Nivolumab or Atezolizumab in the second-line treatment of Advanced Non-small Cell Lung Cancer? A Prognostic Index based on data from Daily Practice. J Clin Med. 2023;12(6).
53.
Hopkins AM, Wagner J, Kichenadasse G, Modi N, Rowland A, Sorich MJ. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy. Int J Cancer. 2020;147(11):3085–9.PubMedCrossRef
54.
Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5.PubMedPubMedCentralCrossRef
55.
Lu H, Yu C, Maimaiti M, Li G. The predictive value of perioperative circulating markers on surgical complications in patients undergoing robotic-assisted radical prostatectomy. World J Surg Oncol. 2023;21(1):179.PubMedPubMedCentralCrossRef
56.
Iwasa YI, Shimizu M, Matsuura K, Hori K, Hiramatsu K, Sugiyama K, et al. Prognostic significance of pre- and post-treatment hematological biomarkers in patients with head and neck cancer treated with chemoradiotherapy. Sci Rep. 2023;13(1):3869.PubMedPubMedCentralCrossRef
57.
Tan Q, Liu S, Liang C, Han X, Shi Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. Thorac cancer. 2018;9(10):1220–30.PubMedPubMedCentralCrossRef
58.
Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine. 2022;101(3):e28617.PubMedPubMedCentralCrossRef
59.
Takenaka Y, Oya R, Takemoto N, Inohara H. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Head Neck. 2022;44(5):1237–45.PubMedCrossRef
60.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef
61.
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.PubMedPubMedCentralCrossRef
62.
Van Wilpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020;9(1):1731942.PubMedPubMedCentralCrossRef
63.
Miholjcic TBS, Halse H, Bonvalet M, Bigorgne A, Rouanne M, Dercle L et al. Rationale for LDH-targeted cancer immunotherapy. European journal of cancer (Oxford, England: 1990). 2023;181:166– 78.
64.
Minami S, Ihara S, Komuta K. Pretreatment lung Immune Prognostic Index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol. 2019;10(1):35–45.PubMedPubMedCentralCrossRef
65.
Zhang T, Xue W, Wang D, Xu K, Wu L, Wu Y, et al. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2021;156:244–50.CrossRef
66.
Zhou Q, Deng G, Wang Z, Dai G. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Front Surg. 2022;9:1002075.PubMedCrossRef
67.
Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG, et al. The prediction potential of the pretreatment lung Immune Prognostic Index for the therapeutic outcomes of Immune checkpoint inhibitors in patients with Solid Cancer: a systematic review and Meta-analysis. Front Oncol. 2021;11:691002.PubMedPubMedCentralCrossRef
Metadata
Title
Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review
Authors
Yusheng Guo
Yao Pan
Jiayu Wan
Bingxin Gong
Yi Li
Xuefeng Kan
Chuansheng Zheng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12271-0

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study

Research

Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study

Research

Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study

Research

Knockdown of ribosome RNA processing protein 15 suppresses migration of hepatocellular carcinoma through inhibiting PATZ1-associated LAMC2/FAK pathway

Research

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Research

HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits